← Back to Screener
Dermata Therapeutics, Inc. Common Stock (DRMA)
Price$1.35
Favorite Metrics
Price vs S&P 500 (26W)-77.63%
Price vs S&P 500 (4W)0.06%
Market Capitalization$5.07M
All Metrics
Book Value / Share (Quarterly)$2.34
P/TBV (Annual)0.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.92
Price vs S&P 500 (YTD)-48.33%
EPS (TTM)$-9.42
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-9.42
EPS (Annual)$-8.16
ROI (Annual)-121.45%
Cash / Share (Quarterly)$2.83
ROA (Last FY)-96.12%
EBITD / Share (TTM)$-8.41
ROE (5Y Avg)-253.80%
Cash Flow / Share (Annual)$-2.92
P/B Ratio0.81x
P/B Ratio (Quarterly)0.38x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-172.30x
ROA (TTM)-102.21%
EPS Incl Extra (Annual)$-8.16
Current Ratio (Annual)4.79x
Quick Ratio (Quarterly)4.59x
3-Month Avg Trading Volume2.00M
52-Week Price Return-84.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.01
52-Week High$9.90
EPS Excl Extra (Annual)$-8.16
26-Week Price Return-73.64%
Quick Ratio (Annual)4.59x
13-Week Price Return-30.77%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.79x
Enterprise Value$-2.454
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.83
3-Month Return Std Dev186.48%
Net Income / Employee (TTM)$-1
ROE (Last FY)-121.45%
Net Interest Coverage (Annual)-67.40x
EPS Basic Excl Extra (Annual)$-8.16
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-9.42
ROI (TTM)-130.89%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.82
Price vs S&P 500 (52W)-114.27%
Year-to-Date Return-45.69%
5-Day Price Return4.13%
EPS Normalized (Annual)$-8.16
ROA (5Y Avg)-149.58%
Month-to-Date Return4.13%
Cash Flow / Share (TTM)$-1.17
EBITD / Share (Annual)$-8.39
ROI (5Y Avg)-253.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-9.42
P/TBV (Quarterly)0.35x
P/B Ratio (Annual)0.38x
Book Value / Share (Annual)$2.34
Price vs S&P 500 (13W)-31.46%
Beta0.61x
Revenue / Share (TTM)$0.00
ROE (TTM)-130.89%
52-Week Low$1.10
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DRMADermata Therapeutics, Inc. Common Stock | — | — | — | — | $1.35 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.